PPARG and Insulin resistance: Telmisartan shows maximal potency on PPARγ when compared to other ARBs and has been reported to reduce insulin resistance in several in vitro,23, 24 animal25, 26 and clinical studies.27–30 Telmisartan also improves adiponectin levels, an important metabolic marker of insulin resistance and atherosclerotic disease, lipid control, and has favourable effects on fasting serum insulin and high sensitivity C reactive protein27 (high-sensitivity C reactive protein (hs-CRP); a marker of CVD).